One underappreciated reason why I feel DXCM could potentially gain more favorable interest is because its long-suffering ...

DexCom reported Q4 revenue of $1.26 billion (up 13% YoY) and finished the year above the high end of guidance, delivering a non‑GAAP gross margin of 63.5%, adjusted EBITDA margin of 33.5%, net income ...

DexCom Inc. reports fourth-quarter earnings Thursday after the market close, with investors eager to gauge whether the continuous glucose monitoring leader can defend its premium market position ...

DexCom, Inc. (DXCM) 47th Annual Raymond James Institutional Investor Conference March 2, 2026 1:05 PM ESTCompany ParticipantsJereme Sylvain - Executive ...

DexCom (NASDAQ: DXCM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) announced new AI-enabled features ...

Glasgow Warriors missed out on the chance to extend their lead at the top of the United Rugby Championship table as Sean ...

Goal of Caliper Accelerator is to enable more consistent integration of device data into EHRs, analytics platforms, and ...

Copyright 2026 BBC. All rights reserved. The BBC is not responsible for the content of external sites. Read about our approach to external linking.

Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.26 billion. The company expects the full ...

Kyle Rowe’s brace ultimately proved in vain for Franco Smith’s squad, who picked up a losing bonus-point as they remain top ...